CV Sciences, Inc. is a life science company that operates through two segments, specialty pharmaceuticals and consumer products. The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol CBD as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate CVSI is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at billion, growing to over billion in the next years.
Quote | CV Sciences Inc. (OTCMKTS:CVSI)
Last: | $0.041 |
---|---|
Change Percent: | -1.28% |
Open: | $0.0395 |
Close: | $0.041 |
High: | $0.0435 |
Low: | $0.0356 |
Volume: | 1,459,834 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | CV Sciences Inc. (OTCMKTS:CVSI)
2024-03-28 11:42:07 ET CV Sciences, Inc. (CVSI) Q4 2023 Earnings Conference Call March 28, 2024, 10:00 AM ET Company Participants Brendan Hawkins - Investor Relations Joseph Dowling - Chief Executive Officer Joerg Grasser - Chief Financial Officer Presentat...
2024-03-28 09:09:43 ET More on CV Sciences Financial information for CV Sciences Read the full article on Seeking Alpha For further details see: CV Sciences Non-GAAP EPS of -$0.02, revenue of $16M
Message Board Posts | CV Sciences Inc. (OTCMKTS:CVSI)
Subject | By | Source | When |
---|---|---|---|
https://www.mdpi.com/1422-0067/24/9/7773 | Thomas@yahoo | investorshub | 05/01/2023 10:42:02 AM |
https://journals.lww.com/clinicalneuropharm/fulltext/9900/medical_cannabis_in_th | Thomas@yahoo | investorshub | 05/01/2023 10:37:36 AM |
https://www.msn.com/en-us/money/companies/battle-over-delta-8-is-heating-up-nati | Dean14 | investorshub | 04/29/2023 1:15:13 PM |
https://link.swansonvitamins.com/view/614df074ee9613022e762f90in90a.9za1/62e9a3e | Thomas@yahoo | investorshub | 04/29/2023 11:38:39 AM |
https://mailchi.mp/42ce7958a786/ushr-advocates-for-2023-farm-bill-priorities-and-fda-regulation-of-c | Thomas@yahoo | investorshub | 04/28/2023 9:59:41 PM |
News, Short Squeeze, Breakout and More Instantly...
Hemp-focused CV Sciences, Inc. (OTCQB:CVSI) announced its financial results on Thursday for the year ended Dec. 31, 2023. The San Diego-based compa...
CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...